Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Danazol for Anemia in Myelofibrosis
NCT01732445Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2013
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and danazol in anemia, primary myelofibrosis (PMF) and secondary myelofibrosis (SMF), sponsored by Mayo Clinic. Primary endpoint: Best Overall Response Rate as Determined by International Working Group Criteria up to 2 years. Started Apr 2013; status: completed.
02
Drugs
ruxolitinibdanazol
03
Conditions
anemiaprimary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on NCT01732445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732445.